Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail
  • Print
  • Share
  • E-mail
-
 
Pediatric Labeling Date:  12/06/2019
 
Trade Name:  Abraxane
 
Generic Name or Proper Name (*):  paclitaxel
 
Indications Studied:  Recurrent or refractory pediatric solid tumors
 
Label Changes Summary:  *Safety and effectiveness in pediatric patients have not been established. *Pharmacokinetics, safety, and antitumor activity were assessed in an open-label, dose escalation, dose expansion study in 96 pediatric patients aged 1.4 to < 17 years with recurrent or refractory pediatric solid tumors. *The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. *No new safety signals were observed in pediatric patients across these studies. *Paclitaxel protein-bound exposures normalized by dose were higher in 96 pediatric patients aged 1.4 to < 17 years as compared to those in adults.
 
BPCA(B):  B
 
Sponsor:  Abraxis BioScience, L.L.C.
 
Pediatric Exclusivity Granted Date:  11/08/2019
 
NNPS:  FALSE
 
Therapeutic Category:  Antineoplastic
 
-
-